Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 15, 2026

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

View original at globenewswire.com

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Gorlin Syndrome represents a compelling development opportunity for SkinJect® given significant unmet medical need, recurring disease nature, lack of approved therapies for pediatric patients, and potential for lesion-directed non-surgical treatment
60% confidence
Patients with Gorlin Syndrome often face a lifetime of recurring surgeries and progressive treatment burden beginning at a young age
60% confidence
If granted, the Rare Pediatric Disease Priority Review Voucher may reduce FDA review time for a future NDA from approximately ten months under standard review to approximately six months under priority review
60% confidence
SkinJect® Phase 2 study showed 64% clinical clearance and 55% complete response, supporting its potential as a non-surgical treatment for Gorlin Syndrome
60% confidence
The 200µg D-MNA treatment arm demonstrated the strongest rates of clinical and histological clearance of 64% and 55% respectively among evaluable nodular BCC patients while maintaining a favorable safety and tolerability profile
60% confidence
SkinJect® and BCC/Gorlin Syndrome together represent a ~$2 billion annual market opportunity
60% confidence
SkinJect® may be uniquely positioned to address both pediatric and adult manifestations of Gorlin Syndrome through a repeatable, lesion-directed treatment approach
60% confidence
Teverelix® represents a ~$6 billion annual market opportunity
60% confidence
If Orphan Drug Designation is granted and a marketing application approved, SkinJect® may be eligible for seven years of U.S. market exclusivity, waiver of certain FDA application fees, and additional regulatory incentives
60% confidence
Gorlin Syndrome affects approximately 1 in 30,000 to 60,000 individuals worldwide, corresponding to a U.S. patient population of approximately 6,000 to 12,000 individuals
60% confidence

Data points we hold from this source

U.S. Food and Drug Administration · parameter count

6 months_priority_review